Drugmaker Merck divests stake in vaccine-maker Moderna

[December 02, 2020]  (Reuters) - U.S. drugmaker Merck & Co said on Wednesday it has sold its equity investment in Moderna Inc, after benefiting from a surge in the stock price of the vaccine developer this year.

Merck did not disclose the details of the sale proceeds, but said it expects to record a small gain from the sale in the fourth quarter of 2020. (https://bit.ly/3og5kil)

Moderna's shares have risen more than seven-fold this year, valuing the company at $55.80 billion as of Tuesday's closing price.

Moderna is one of the front-runners in the race to develop a coronavirus vaccine, and on Monday filed for U.S. emergency use authorization of its vaccine.

Merck, which had invested $50 million in Moderna in 2015, said it would retain exposure to the company indirectly through its investment in venture funds.

(Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva and Shinjini Ganguli)

[© 2020 Thomson Reuters. All rights reserved.]

Copyright 2020 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.